dengu
widespread
vectorborn
viral
diseas
caus
dengu
viru
denv
safe
effect
drug
approv
clinic
use
use
sequenti
antigen
pan
yeast
antibodi
librari
deriv
healthi
donor
denv
envelop
protein
domain
iii
diii
combin
deplet
entri
defect
diii
mutant
identifi
crossreact
human
monoclon
antibodi
mab
bound
high
affin
denv
diii
four
denv
serotyp
immunogenet
analysi
indic
germlinelik
mab
somat
mutat
closest
vh
germlin
gene
importantli
demonstr
potent
neutral
denv
vitro
mous
model
denv
infect
without
detect
antibodydepend
enhanc
ade
effect
epitop
map
highli
conserv
region
diii
may
guid
design
effect
dengu
vaccin
immunogen
furthermor
first
germlinelik
mab
deriv
antibodi
librari
could
neutral
four
denv
serotyp
tool
explor
mechan
denv
infect
promis
therapeut
candid
dengu
viru
infect
million
peopl
year
infect
initi
entri
viru
cell
mediat
viral
envelop
glycoprotein
four
close
relat
plo
pathogen
http
doidenv
serotyp
antigen
distinct
compris
sever
genotyp
exhibit
differ
infect
characterist
mosquito
vector
human
host
one
confound
problem
face
vaccin
biolog
drug
develop
decad
inabl
antibodi
one
serotyp
protect
infect
anoth
one
instead
induc
humor
immun
respons
one
dengu
viru
infect
enhanc
infect
diseas
process
brought
subsequ
infect
anoth
dengu
serotyp
studi
use
competit
sort
strategi
interrog
human
antibodi
librari
identifi
crossreact
mab
design
four
denv
serotyp
mab
possess
somat
mutat
closest
vh
germlin
gene
high
affin
diii
importantli
germlinelik
demonstr
broad
spectrum
neutral
four
denv
serotyp
thu
promis
candid
therapeut
epitop
may
impli
design
effect
vaccin
immunogen
elicit
antibodi
vivo
broadli
neutral
germlinelik
human
monoclon
antibodi
dengu
viru
plo
pathogen
http
denv
e
protein
consist
di
dii
diii
shown
green
cyan
light
pink
respect
scfv
display
rose
red
fusion
protein
surfac
yeast
antibodi
express
detect
use
fluoresc
anticmyc
antibodi
green
bind
scfv
biotinyl
diii
detect
use
peconjug
streptavidin
red
ha
hemagglutinin
vl
variabl
light
chain
vh
variabl
heavi
chain
g
gli
ser
flexibl
peptid
linker
b
schemat
scfv
pan
process
biotinyl
diii
shown
fluoresc
tag
color
red
use
antigen
biopan
ten
time
concentr
unbiotinyl
diii
mutant
use
competitor
mac
facsbas
sort
strategi
use
isol
high
affin
binder
yeastdisplay
antibodi
librari
broadli
neutral
germlinelik
human
monoclon
antibodi
dengu
viru
plo
pathogen
http
doi
dengu
viru
denv
caus
preval
mosquitoborn
viral
diseas
billion
peopl
risk
infect
countri
million
infect
symptom
die
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
year
specif
antivir
drug
avail
denv
infect
approv
vaccin
dengvaxia
caus
consider
controversi
regard
safeti
potenti
benefit
decad
antidenv
vaccin
biolog
drug
develop
hamper
high
sequenc
diverg
among
four
denv
serotyp
diverg
lead
fact
one
antibodi
may
suffici
neutral
denv
infect
instead
induc
humor
immun
respons
one
denv
infect
enhanc
infect
diseas
process
brought
subsequ
infect
anoth
denv
serotyp
find
suggest
develop
new
broadli
neutral
antibodi
serotyp
denv
could
promis
candid
antidenv
agent
may
also
guid
design
effect
safe
vaccin
immunogen
denv
envelop
glycoprotein
e
protein
mediat
viru
entri
cell
major
neutral
target
antibodi
e
protein
type
ii
fusion
protein
consist
three
domain
di
dii
diii
diii
propos
contain
receptor
bind
domain
recent
studi
reveal
crossreact
conserv
epitop
exist
dii
well
diii
denv
e
protein
naturallyoccur
primari
denv
infect
larg
fraction
antibodi
repertoir
consist
diispecif
antibodi
unfortun
typic
poor
neutral
may
increas
likelihood
sever
diseas
upon
subsequ
infect
mechan
known
antibodydepend
enhanc
ade
contrast
antibodi
target
diii
proven
potent
neutral
antibodi
could
elicit
natur
infect
individu
despit
previou
studi
indic
antidenv
diii
serotypespecif
crossreact
antibodi
could
elicit
use
denv
diii
vaccin
immunogen
infect
human
also
demonstr
lysin
posit
diii
critic
residu
crossreact
epitop
therefor
conserv
epitop
diii
repres
attract
target
develop
broadli
neutral
denv
antibodi
report
isol
potent
denv
diiispecif
human
monoclon
antibodi
mab
design
larg
antibodi
librari
construct
blood
healthi
adult
donor
competit
sort
strategi
use
diii
mutant
competitor
appli
identifi
antibodi
precis
target
conserv
neutral
epitop
knowledg
first
human
mab
isol
antibodi
librari
could
neutral
four
serotyp
denv
virus
importantli
heavi
light
chain
gene
close
put
germlin
predecessor
fulli
human
origin
germlinelik
natur
combin
highaffin
broad
neutral
activ
toward
denv
serotyp
suggest
promis
candid
antivir
agent
may
also
provid
uniqu
templat
design
effect
dengu
vaccin
immunogen
previous
prepar
larg
antibodi
librari
use
peripher
blood
b
lymphocyt
nonimmun
healthi
donor
use
panningscreen
viral
cancer
target
studi
use
competit
librari
sort
strategi
isol
broadli
neutral
antibodi
fig
yeastdisplay
singl
chain
antibodi
fragment
scfv
librari
use
screen
biotinyl
denv
diii
importantli
ten
time
concentr
unbiotinyl
diii
mutant
use
competitor
yeast
cell
select
present
antibodyexpress
cell
could
bind
well
wildtyp
diii
instead
diii
mutant
result
isol
antibodi
target
crossreact
neutral
epitop
cover
residu
potent
enrich
achiev
four
round
sort
panel
antibodi
identifi
fig
two
antibodi
design
bound
potent
denv
diii
scfv
gene
fuse
human
fc
protein
express
surfac
plasmon
reson
spr
experi
use
evalu
antigen
bind
equilibrium
dissoci
constant
k
diii
nm
nm
nm
nm
respect
mab
display
broader
bind
profil
compar
k
nm
nm
nm
nm
respect
tabl
fig
improv
affin
four
denv
serotyp
construct
mutant
librari
use
errorpron
pcr
technolog
follow
three
cycl
mutagenesi
select
two
clone
identifi
enrich
pool
yeast
sort
design
biacor
analysi
show
crossreact
bind
activ
diii
preserv
affin
matur
process
k
diii
nm
pm
pm
nm
respect
fig
although
bind
diii
improv
slightli
increas
bind
affin
diii
compar
parent
mab
notabl
exhibit
high
affin
denv
diii
k
nm
nm
nm
nm
respect
demonstr
could
bind
four
serotyp
denv
virus
high
avid
tabl
fig
also
assess
bind
specif
elisa
result
show
weak
crossreact
zika
viru
zikv
diii
bind
irrelev
antigen
fig
next
assess
neutral
capac
four
denv
serotyp
use
denv
luciferas
report
viral
particl
rvp
neutral
assay
use
denv
rvp
four
dengu
serotyp
common
strain
denv
research
westpac
luminesc
report
express
proport
number
rvp
ad
bhk
dcsign
cell
confirm
linear
correl
extent
rvp
infect
report
gene
express
consist
biacor
bind
result
could
neutral
four
serotyp
denv
display
better
neutral
neutral
titer
ic
evalu
neutral
breadth
igg
four
denv
serotyp
standard
plaqu
reduct
neutral
assay
prnt
cell
perform
use
live
virus
includ
genbank
fig
isol
infect
patient
guangzhou
china
genbank
genbank
genbank
irrelev
human
mab
use
neg
control
broadli
neutral
mab
four
denv
serotyp
use
posit
control
shown
fig
igg
could
neutral
four
denv
serotyp
neutral
titer
ic
respect
tabl
next
use
wellestablish
ade
assay
detect
vitro
ade
effect
igg
mutat
form
igg
also
gener
contain
leucin
alanin
substitut
posit
igglala
lack
bind
receptor
ade
effect
igg
igglala
well
measur
interestingli
neither
igg
igglala
present
ade
effect
differ
serotyp
denv
fig
fig
contrast
potent
ade
effect
observ
diispecif
mab
result
show
igg
denv
diiispecif
mab
without
detect
ade
effect
analyz
sequenc
mab
use
imgt
tool
identifi
closest
vh
germlin
gene
result
indic
origin
differ
bcell
lineag
tabl
vh
gene
deriv
gene
contrast
vh
gene
deriv
gene
interestingli
found
encod
gene
close
resembl
correspond
germlin
gene
segment
notabl
vh
gene
share
sequenc
ident
germlin
respect
fig
result
indic
mab
germlinelik
antibodi
gener
could
show
better
drug
properti
lower
immunogen
compar
somat
hypermut
antibodi
investig
immunogenet
characterist
antibodi
analyz
detail
recombin
frequenc
specif
ighd
ighj
gene
famili
immunoglobulin
igm
repertoir
health
adult
donor
neonat
igm
repertoir
newborn
babi
use
nextgener
sequenc
data
previous
gener
antibodyom
studi
queri
sequenc
igm
repertoir
sequenc
found
display
v
j
recombin
gene
total
sequenc
healthi
adult
igm
repertoir
igm
repertoir
newborn
babi
similar
recombin
frequenc
also
observ
sequenc
v
j
recombin
found
sequenc
analysi
show
one
frequent
use
ighv
gene
identifi
mani
sequenc
share
signific
degre
resembl
fig
brief
analysi
data
show
potenti
elicit
robust
immun
respons
germlin
antibodi
vaccin
determin
whether
protect
denv
infect
vivo
firstli
use
lethal
infect
suckl
mous
model
mice
challeng
pfumous
via
intracrani
inject
four
hour
later
mice
treat
intracrani
singl
dose
igg
igglala
mutant
unrel
antibodi
control
anim
monitor
morbid
mortal
daili
shown
fig
mice
control
group
die
denv
infect
die
within
first
two
week
viral
challeng
interestingli
signific
differ
therapeut
efficaci
infect
lalamut
igg
protect
infect
wherea
c
germlineroot
circular
phylogenet
tree
antibodi
sequenc
found
igm
librari
deriv
healthi
human
adult
neonat
sequenc
show
highest
similar
shown
red
sequenc
id
start
cb
repres
sequenc
deriv
neonat
start
hh
repres
sequenc
deriv
healthi
adult
phylogenet
tree
construct
neighborjoin
method
http
lalamut
protect
respect
therefor
detect
ade
confirm
vitro
vivo
experi
also
use
typesi
ii
ifn
receptor
defici
mice
test
therapeut
effect
fig
result
show
mice
control
antibodi
treatment
group
die
surviv
rate
mice
reach
treatment
group
indic
antibodi
also
protect
lethal
infect
mice
taken
togeth
result
indic
protect
infect
vivo
map
epitop
germlinelik
mab
identifi
greater
detail
structur
basi
denv
neutral
employ
multipl
approach
fig
sequenc
align
differ
denv
genotyp
map
conserv
amino
acid
residu
denv
diii
show
four
serotyp
denv
diii
amino
acid
residu
differ
one
anoth
amino
acid
fig
subsequ
serotyp
deriv
diii
consensu
gene
randomli
mutat
construct
yeastdisplay
mutant
librari
two
round
sort
yeast
cell
show
express
surfac
lack
bind
perform
total
bind
escap
mutant
align
serotyp
consensu
protein
sequenc
mutat
frequenc
posit
plot
residu
posit
number
similarli
uniqu
diii
sequenc
deriv
natur
isol
serotyp
dengu
virus
genebank
also
align
consensu
sequenc
fig
superimpos
profil
two
set
sequenc
show
mani
escap
mutat
locat
wellconserv
area
indic
broad
crossreact
natur
isol
dengu
virus
besid
epitop
map
show
epitop
close
partial
overlap
dimer
interfac
domain
ii
iii
result
may
explain
potent
crossreact
antibodi
four
denv
serotyp
furthermor
comput
dock
denv
antibodi
complex
perform
use
zdock
method
select
three
top
score
dock
complex
contain
key
residu
identifi
experiment
epitop
map
approach
one
top
score
dock
model
exhibit
minimum
clash
appropri
protein
interfac
paramet
use
demonstr
lactat
potenti
epitop
interact
antibodi
might
shed
light
molecular
mechan
broadli
crossreact
neutral
fig
show
dock
model
antibodi
complex
epitop
highlight
green
surfac
dock
model
reveal
differ
orient
antibodi
bind
compar
diii
complex
structur
fab
previous
determin
epitop
compris
three
structur
proxim
region
residu
green
dark
green
ctermin
lime
one
key
residu
contact
germlin
mutat
complex
structur
residu
contact
hydrophob
residu
ile
trp
contact
center
part
epitop
loop
also
involv
bind
surfac
area
interfac
diii
antibodi
model
complex
typic
antibodyantigen
interact
six
hydrogen
bond
like
form
salt
bridg
interfac
brief
bind
region
may
close
partial
overlap
dimer
interfac
domain
ii
iii
might
indic
broad
crossreact
four
serotyp
denv
dengu
diseas
complex
immun
respons
orchestr
host
cell
partial
due
presenc
four
serotyp
denv
importantli
primari
denv
infect
one
protect
aggrav
secondari
infect
differ
serotyp
bring
mani
difficulti
develop
effect
vaccin
thu
urgent
develop
effect
crossreact
antivir
therapi
denv
infect
monoclon
antibodi
mab
grow
import
protect
pathogen
immun
respons
virus
present
mani
therapeut
antibodi
treat
viral
infect
develop
antibodi
sarscov
merscov
nipah
hendra
virus
influenza
viru
fortun
screen
antibodi
larg
librari
enabl
rapid
develop
highaffin
human
mab
especi
rapid
respons
outbreak
emerg
virus
diseas
recent
success
identifi
two
human
germlinelik
mab
merscov
influenza
viru
librari
name
respect
natur
exist
low
level
somat
hypermut
librari
potent
bind
activ
envelop
protein
merscov
influenza
viru
importantli
show
highli
therapeut
effect
anim
model
therefor
librari
screen
quickli
use
isol
germlinelik
antibodi
effect
bind
complex
protein
target
like
denv
virus
increas
neutral
breadth
key
issu
develop
antidenv
antibodi
previou
studi
reveal
two
class
broadli
neutral
antibodi
flavivirus
includ
antibodi
target
conserv
epitop
dii
diii
conserv
fusion
loop
epitop
fle
dii
immunodomin
epitop
e
protein
unfortun
epitop
frequent
induc
poorli
neutral
strongli
infectionenhanc
antibodi
via
ade
therefor
diii
repres
ideal
target
neutral
antibodi
studi
appli
highli
effici
yeastdisplaybas
sort
strategi
use
highli
divers
denv
diii
antigen
competit
sort
techniqu
appli
method
quickli
effici
identifi
two
human
germlinelik
broadspectrum
antidenv
mab
scfv
yeast
librari
use
diii
antigen
make
promis
candid
therapeut
well
templat
vaccin
develop
anoth
class
highli
effici
broadli
neutral
antibodi
target
envelop
dimer
epitop
ede
secondari
acut
denv
infect
plasmablast
identifi
dejnirattisai
et
al
antibodi
may
especi
get
high
somat
mutat
secondari
viru
infect
compar
highli
somat
mutat
antibodi
germlinelik
antibodi
typic
better
safeti
drugrel
properti
importantli
hendra
nipah
antibodi
near
germlin
antibodi
exhibit
good
drugabl
similar
librari
also
use
isol
antibodi
success
candid
therapeut
mab
anim
model
also
complet
phase
clinic
trial
without
side
effect
improv
affin
four
serotyp
denv
diii
subject
affin
matur
process
name
subsequ
analyz
sequenc
use
imgt
tool
identifi
closest
vh
germlin
gene
interestingli
found
still
germlinelik
antibodi
although
went
mutat
process
vitro
ident
vh
gene
germlin
respect
order
evalu
neutral
effect
igg
use
standard
plaqu
reduct
neutral
cell
measur
denv
infect
neutral
igg
show
broadli
neutral
toward
four
serotyp
denv
well
recent
denv
isol
clinic
sampl
importantli
present
ade
effect
differ
serotyp
denv
vivo
studi
result
demonstr
therapeut
potenti
sever
infect
brief
could
neutral
four
serotyp
denv
vitro
protect
denv
infect
mous
model
vivo
without
detect
ade
effect
therefor
expect
like
drugabl
could
develop
candid
therapeut
futur
also
local
epitop
use
combin
comput
structur
model
displaybas
antigen
mutagenesi
sequencebas
analysi
mutant
epitop
appear
overlap
epitop
previous
explor
target
crossreact
murin
mab
close
partial
overlap
dimer
interfac
domain
ii
iii
indic
epitop
could
import
compon
vaccin
immunogen
intend
elicit
crossreact
neutral
antibodi
progress
experi
crystal
complex
denv
diii
would
allow
precis
determin
epitop
major
result
studi
identif
germlinelik
human
mab
yeast
antibodi
librari
bind
high
picomolar
affin
diii
serotyp
neutral
four
denv
serotyp
two
major
implic
find
potenti
candid
therapeut
could
develop
preclin
clinic
set
epitop
germlinelik
mab
could
guid
design
effect
candid
vaccin
immunogen
capabl
elicit
andor
antibodi
cell
cultiv
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
bovin
serum
fb
biowest
mosquito
cell
cultur
medium
supplement
fb
cell
maintain
humidifi
atmospher
co
incub
except
cell
cultiv
genbank
isol
infect
patient
guangzhou
genbank
genbank
genbank
propag
cell
use
rpmi
medium
titer
measur
standard
plaqu
form
assay
cell
denv
diii
gene
serotyp
synthes
genescript
inc
nanj
china
fuse
fc
ctermin
avitag
clone
psectag
express
vector
serotyp
mutant
gener
overlap
pcr
convers
scfv
heavi
light
chain
scfv
amplifi
reclon
vector
plasmid
transfect
cell
thermo
fisher
transient
express
purifi
use
protein
g
column
ge
healthcar
piscataway
nj
accord
manufactur
instruct
purifi
protein
biotinyl
mix
biotinyl
reagent
pb
min
ice
accord
manufactur
instruct
pierc
larg
yeastdisplay
scfv
librari
use
antibodi
screen
screen
protocol
essenti
carri
describ
previous
briefli
binotinyl
cell
initi
librari
mix
wash
pbsa
incub
streptavidin
conjug
microbead
miltenyi
biotec
auburn
ca
load
onto
automac
system
miltenyi
biotec
sort
three
round
sort
downsiz
librari
sort
binotinyl
also
use
unbiotinyl
mutant
competitor
gener
scfv
scfv
mutant
librari
random
mutagenesi
scfv
gene
perform
errorpron
pcr
use
genemorph
ii
kit
stratagen
follow
manufactur
instruct
minor
modif
diversifi
mutat
profil
um
two
nucleotid
analogu
triphosph
mix
pcr
reaction
mixtur
second
third
cycl
librari
construct
extra
step
dna
shuffl
pcr
insert
regular
pcr
cycl
combin
benefici
mutat
obtain
previou
matur
process
dna
shuffl
pcr
step
perform
follow
cycl
denatur
second
follow
annealingextens
second
biorad
mycycl
bind
affin
scfv
scfv
scfv
scfv
denv
diii
analyz
surfac
plasmon
reson
technolog
use
biacor
instrument
ge
healthcar
antibodi
coval
immobil
onto
sensor
chip
use
carbodiimid
coupl
chemistri
control
refer
surfac
prepar
nonspecif
bind
refract
index
chang
analysi
kinet
interact
vari
concentr
antigen
inject
flow
rate
use
run
buffer
contain
hepe
mm
nacl
mm
edta
surfact
ph
associ
dissoci
phase
data
fit
simultan
langumir
global
model
use
nonlinear
data
analysi
program
biaevalu
experi
done
neutral
activ
mab
measur
use
standard
plaqu
reduct
neutral
cell
previous
describ
briefli
serial
dilut
mab
ad
approxim
pfu
varieti
dengu
viru
strain
incub
h
mixtur
ad
cell
monolay
plate
duplic
incub
h
mixtur
remov
ml
wv
lmp
agaros
promega
dmem
plu
vv
fb
layer
onto
infect
cell
incub
day
well
stain
wv
crystal
violet
dissolv
vv
formaldehyd
visual
plaqu
prnt
valu
determin
use
nonlinear
regress
analysi
prnt
data
calcul
nonlinear
regress
analysi
use
sigmaplot
version
systat
softwar
inc
ca
previous
describ
denv
rvp
four
serotyp
preincub
equal
volum
serial
dilut
antibodi
predilut
predilut
measur
base
dilut
antibodi
prior
combin
rvp
dmem
infect
media
h
room
temperatur
transfer
well
plate
equal
volum
denv
rvp
ad
well
follow
slow
agit
h
room
temperatur
bhk
dcsign
cell
ad
well
densiti
cell
per
well
follow
incub
co
h
cell
subsequ
fix
lyse
analyz
luminesc
report
express
use
wallac
victor
percent
infect
concentr
mab
serum
calcul
raw
data
express
percent
infect
versu
log
mab
concentr
reciproc
serum
dilut
data
fit
sigmoid
doserespons
curv
use
prism
graphpad
softwar
la
jolla
ca
determin
titer
antibodi
achiev
reduct
infect
maximum
infect
determin
absenc
antibodi
vitro
ade
assay
perform
use
cell
briefli
serial
dilut
antibodi
concentr
rang
mix
incub
h
mixtur
ad
cell
multipl
infect
h
plate
cell
subsequ
wash
time
serum
free
medium
collect
cell
centrifug
cell
pellet
resuspend
medium
contain
fb
ad
plate
incub
day
co
titer
virus
supernat
measur
use
plaqu
assay
ade
effect
calcul
differ
viral
yield
supernat
infect
presenc
ad
antibodi
epitop
map
perform
use
previous
describ
protocol
briefli
random
mutagenesi
denv
gene
perform
use
genemorph
ii
kit
stratagen
describ
yeastdisplay
mutant
librari
mix
biotinyl
scfvfc
wash
stain
mous
anticmyc
antibodi
roch
conjug
goatantimous
antibodi
invitrogen
peconjug
streptavidin
invitrogen
two
round
sort
facsaria
ii
cell
sorter
bd
biocsienc
san
jose
ca
sort
cell
amplifi
plasmid
prepar
sequenc
homolog
model
variabl
region
heavi
v
h
light
v
l
chain
scfv
antibodi
carri
use
swissmodel
workspac
select
closest
templat
structur
pdb
code
heavi
chain
light
chain
whose
sequenc
similar
respect
v
h
v
l
orient
scfv
structur
assign
similar
one
templat
pdb
code
show
minimum
steric
clash
creat
final
scfv
model
crystal
structur
denv
diii
serotyp
pdb
code
use
dock
model
scfv
antibodi
dock
scfv
dengu
enviii
perform
zdock
server
http
zdockbuedu
use
fast
fourier
transform
fft
base
rigidbodi
protein
dock
algorithm
score
function
combin
pairwis
shape
complementar
desolv
electrostat
energi
base
escap
mutant
led
loss
epitop
avail
crystal
structur
denv
diii
select
list
residu
biolog
constrain
surfac
envdiii
potenti
contact
residu
dock
constraint
similarli
one
two
residu
loop
chosen
dock
interfac
loop
domin
hydrophob
residu
wherea
germlin
mutat
high
antigencontact
propens
result
top
zdock
predict
filter
use
userdefin
residu
angstrom
distanc
cutoff
three
predict
complex
kept
residu
select
come
togeth
interfac
examin
pdbepisa
protein
interfac
surfac
assembl
pymol
use
analysi
dock
model
graphic
illustr
suckl
mice
purchas
b
k
univers
group
limit
shanghai
china
hous
specif
pathogenfre
condit
anim
facil
shanghai
public
health
clinic
center
fudan
univers
shanghai
china
infect
mice
transfer
anim
biosafeti
level
laboratori
shanghai
china
one
day
mice
use
experi
mice
intracerebr
inject
pfu
h
post
infect
mice
passiv
transfer
singl
dose
antibodi
igg
igg
lala
mutant
igg
neg
control
via
intracerebr
inject
surviv
rate
diseas
sing
monitor
daili
mice
type
type
ii
interferon
receptordefici
purchas
b
k
univers
group
limit
shanghai
china
hous
specif
pathogenfre
condit
anim
facil
shanghai
public
health
clinic
center
fudan
univers
shanghai
china
infect
mice
transfer
laboratori
shanghai
china
group
mixedsex
mice
use
experi
mice
intraperiton
inject
pfu
volum
h
post
infect
mice
passiv
transfer
singl
dose
antibodi
igglala
antibodi
control
via
ip
inject
surviv
rate
weight
loss
diseas
sing
monitor
daili
specificpathogenfre
mice
week
old
suckl
mice
use
experi
experiment
protocol
review
approv
institut
committe
